VistaGen Therapeutics Statistics Share Statistics VistaGen Therapeutics has 30.68M
shares outstanding. The number of shares has increased by 10.19%
in one year.
Shares Outstanding 30.68M Shares Change (YoY) 10.19% Shares Change (QoQ) 5.22% Owned by Institutions (%) 48.52% Shares Floating 27.73M Failed to Deliver (FTD) Shares 19,994 FTD / Avg. Volume 3.71%
Short Selling Information The latest short interest is 1.16M, so 3.79% of the outstanding
shares have been sold short.
Short Interest 1.16M Short % of Shares Out 3.79% Short % of Float 6.17% Short Ratio (days to cover) 3.5
Valuation Ratios The PE ratio is -1.49 and the forward
PE ratio is -2.22.
VistaGen Therapeutics's PEG ratio is
-0.15.
PE Ratio -1.49 Forward PE -2.22 PS Ratio 157.98 Forward PS 194.1 PB Ratio 1.09 P/FCF Ratio -1.82 PEG Ratio -0.15
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for VistaGen Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.51,
with a Debt / Equity ratio of 0.02.
Current Ratio 6.51 Quick Ratio 6.51 Debt / Equity 0.02 Debt / EBITDA -0.03 Debt / FCF -0.04 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $10.13K Profits Per Employee $-1.07M Employee Count 48 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax 7K Effective Tax Rate -0.01%
Stock Price Statistics The stock price has increased by 21.26% in the
last 52 weeks. The beta is 0.54, so VistaGen Therapeutics's
price volatility has been higher than the market average.
Beta 0.54 52-Week Price Change 21.26% 50-Day Moving Average 3.23 200-Day Moving Average 2.7 Relative Strength Index (RSI) 62.23 Average Volume (20 Days) 538,709
Income Statement In the last 12 months, VistaGen Therapeutics had revenue of 486K
and earned -51.42M
in profits. Earnings per share was -1.67.
Revenue 486K Gross Profit 486K Operating Income -55.97M Net Income -51.42M EBITDA -55.34M EBIT -55.97M Earnings Per Share (EPS) -1.67
Full Income Statement Balance Sheet The company has 67.13M in cash and 1.51M in
debt, giving a net cash position of 65.62M.
Cash & Cash Equivalents 67.13M Total Debt 1.51M Net Cash 65.62M Retained Earnings -407.63M Total Assets 68.92M Working Capital 55.56M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -42.1M
and capital expenditures -191K, giving a free cash flow of -42.29M.
Operating Cash Flow -42.1M Capital Expenditures -191K Free Cash Flow -42.29M FCF Per Share -1.38
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -11517.08% and -10579.84%.
Gross Margin 100% Operating Margin -11517.08% Pretax Margin -10578.4% Profit Margin -10579.84% EBITDA Margin -11386.42% EBIT Margin -11517.08% FCF Margin -8701.23%
Dividends & Yields VTGN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for VTGN.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 7, 2023. It was a
backward
split with a ratio of 1:30.
Last Split Date Jun 7, 2023 Split Type backward Split Ratio 1:30
Scores Altman Z-Score -5.25 Piotroski F-Score 1
